Premium
Azacitidine‐associated haemorrhagic enteritis in a case of myelodysplastic syndrome: A case report
Author(s) -
Hagino Takeshi,
Shinomiya Wataru,
Hidai Hiroko,
Umeda Miki,
Kurimoto Miwa,
Saga Reina,
Tsutsumi Hisashi,
Shibata Yoshiaki,
Akiyama Hideki,
Motomura Sayuri
Publication year - 2020
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.13146
Subject(s) - medicine , enteritis , azacitidine , myelodysplastic syndromes , adverse effect , gastroenterology , pediatrics , bone marrow , gene expression , dna methylation , gene , biochemistry , chemistry
What is known and objective 5‐Azacitidine (AZA) is an agent widely used to treat myelodysplastic syndrome (MDS). Case description We herein report an 83‐year‐old woman diagnosed with MDS who was treated with AZA. She tolerated the first cycle of AZA; however, severe adverse events involving haemorrhagic enteritis with multiple intestinal ulcers developed after the second and third cycles. Additionally, the interval between the administration of AZA and the development of haematochezia shortened with each cycle of AZA. What is new and Conclusion We herein report as‐yet‐undescribed potential side effects, AZA‐associated haemorrhagic enteritis that should be kept in mind.